Bluechiip Limited (ASX: BCT)present.knowledgevision.com/account/brr/assets/...Bluechiip Limited (BCT) should refer to all BCT ASX releases and statutory reports before considering

1 Brett Schwarz (MD/CEO) [email protected] +61 419 367 590

Bluechiip Limited (ASX: BCT)Delivering unique tracking and monitoring solutions

3rd Annual Australian Microcap Investment Conference16 October 2012

mailto:[email protected]


Introductory video


3

Agenda

1. Company Overview

2. Market & Need

3. The bluechiip® Tracking Solution

4. Commercialisation Strategy

5. Opportunity and Next Steps

6. Q&A

Brett Schwarz (MD/CEO) [email protected] +61 419 367 590


4

Disclaimer

Material used in this presentation is a summary of available information,and while given in good faith, is professional opinion only. Any investor inBluechiip Limited (BCT) should refer to all BCT ASX releases and statutoryreports before considering investment in the company.

Certain information may have been derived from third parties and thoughBCT has no reason to believe that it is not accurate, reliable or complete, ithas not been independently audited or verified by BCT.

Any forward-looking statements in this presentation involve subjectivejudgment and analysis and are subject to uncertainties, risks andcontingencies, many of which are outside control of, and maybe unknownto, BCT. Neither BCT, nor its officers, employees and advisors make or giveany representation, warranty or guarantee in relation to this presentation.

BCT reserves right to update, amend or supplement information in thispresentation at any time in its absolute discretion without incurring anyobligation to do so.



COMPANY OVERVIEW

6

Bluechiip in summary

Go-to-market strategy - backed by Tier 1 manufacturing and

commercial partners

‘Platform’ technology – numerous market applications

Recently entered commercialization phase with first sales and now

gearing for growth - next phase to unlock shareholder value

Patented technology solution that clearly addresses market needs

- 100% owned by Bluechiip

bluechiip® will be the gold standard/best practice to enable

temperature chain-of-custody tracking and reporting

First target market is biobanking – significantly broad and growing

rapidly with immediate need

Bluechiip Ltd is an ASX-listed technology company that provides a unique sample management tracking tool initially for the life science market



MARKET & NEED

Biobanking - growing and globalfirst target market

• Definition: Collection, processing, storing and distribution of biospecimens and associated data

• Biobanks (or biorepositories)• Bioresource, translational and life science laboratories• Pharmaceutical sample management facilities• Clinical trial and biomedical research laboratories• Commercial laboratories/biorepositories

• Biospecimens - blood, tissue, urine, saliva, cells, RNA/DNA and hair

• Currently ~2B biospecimens stored around world; growing at ~200M samples p.a.

TIME March 2009

• Growth areas• Cord Blood• Regenerative medicine/stem cell

research for new therapies• Cell lines• In vitro fertilization (IVF)• Clinical trials

8Source: Biobanking for Medical R&D: Technology and Market 2010-2025 by visiongain



9

Biobanking - immediate need/market pull

• Historical labeling and tracking techniques do NOT provide understanding of temperature and other variables that effect sample integrity

Labels(hand-written/pre-printed)

• Labels fall off• Transcription errors• Can’t sense temperature

Barcodes (linear/2D)

• Need line of sight• Significantly decreased reading

reliability in humidity and frost environments

• Can’t sense temperature

RFID • Not able to survive plastic injection molding process

• Not able to survive high temperatures of sterilization and gamma irradiation

• Not able to survive AND operate in low temperatures down to -196ºC

• Can’t sense temperature



THE BLUECHIIP®

TRACKING SOLUTION

bluechiip® - integrated system solution

Crogenic delta tag isembedded into acryovial for use inbiobanks in research

Cryotag is designedspecifically for racksand bags and is readusing Retriever™wand interface

Racks are madespecfically forBluechiip withhandle andmounting holesfor Cryotag

Matchbox™ reader is central go topoint of using bluechiip® system. Itconsists of Matchbox™ unit andRetriever™ wand

Stream™ software isprovided as a stand-alone program withMatchbox™ Readerand as a separateinstall on a server

Temperature chain-of-custody

can only be tracked with bluechiip®

Cryovial

Cryotag

Racks

Matchbox™ readers

Stream™ software

Cryogenic delta tag



12

System based around patentedbluechiip® tag (chip + antenna)

• Electronic license plate (unique ID) with temperature sensing capabilities

• MEMS technology – purely mechanical device - no electronics

• Survives and operates in extreme temperatures (+60ºC to -196ºC)

• Senses and records temperature history

• Highly reliable - reads in frost

• Secure

• Easily molded into consumables

• Immune to gamma irradiation (used for sterilization)

Chip

Antenna



13

Addressing needs - benefits of adoptingbluechiip® tracking solution

Reads temperature at sample level

Increases understanding of factors that affect sample integrity

Unique value add for bioservices

Enhances sample security

Reduces sample handling and breakage

Single tag tracks both ID and temperature

Increases value of sample management

Robust temperature annotation

Facile integration into operations

Outcome: Fit for purpose and evidence based sample management and quality assurance



14

Technology protected bystrong IP portfolio

• All IP wholly owned by Bluechiip

• Patents

• Portfolio of 15 patents over 7 patent families

• 6 granted in USA and Europe

• Some patent applications currently under examination and awaiting examiners report

• Progress patent applications from Provisional PCT National Phase

over coming year

• Continue to build portfolio by filing new patent applications for further protection

• Established Freedom-to-Operate (FTO)

• Trade marks

• Trade marks (word and logo) registered in Australia and USA



COMMERCIALISATION STRATEGY

16

Commercialisation strategy

• Direct sales and through distribution/channel partners

• Recently appointed Commercial Director

• In discussion with global distributors/channel partners

• Corning Life Sciences evaluating technology

• Securing strategic partners who provide avenues to market

• Implementing an Early Adopter Program (EAP)

• Enrolled ATCC and Gentris Corporation

• Seeking others around globe to join EAP

• Commercial launch early 2013

• Production partners secured for each product with Tier 1 corporations

• Chips/tags – STMicroelectronics NV (NYSE: STM) - facilities in Italy

• Consumables (cryovials) – sourcing contract manufacturer in Asia

• Readers – Plexus Corp. (NASDAQ: PLXS) - facility in Penang, Malaysia

• Accessories (cryotags and racks) - RC Precision Engineering - facility in Penang, Malaysia



17

Future market applications

Other Healthcare Markets Non-Healthcare Markets

1. Pathology

2. Clinical trials

3. Pharmaceutical

4. Seed banks

5. Forensics

6. Blood products

7. Diagnostics

8. Research

9. Biological sensing

10. DNA

11. Allograft i.e. heart valves

12. Medical waste

13. Security

14. Defense

15. Cold chain logistics/supply chain

16. Courier companies

17. Aerospace/aviation

18. Industrial

19. Manufacturing



OPPORTUNITY AND NEXT STEPS

19

Corporate summary


Board & Management Key Statistics (as at October 2012)

Iain Kirkwood (Chairman & Non-Executive Director)

Brett Schwarz (Managing Director & CEO)

Joe Baini (Non-Executive Director)

Ron Finkel (Non-Executive Director)

Lee Mitchell (Company Secretary)

Dr Jason Chaffey (CTO)

Brett Roberts (Commercial Director)

ASX Code BCT

Current Share Price: $0.25

52 Week High/Low: $0.30/$0.11

Shares on Issue: 86.8 million

Options (unlisted): 27.1 million

Market Capitalisation $21.7 million

Net Cash: ~$1.0 million

Operating expenses: ~$200-250k per month

Share Price Performance Major Shareholders (as at October 2012)

Holder Name %

Dr Stephen Woodford; Dr Stephen

Woodford & Patricia Woodford 16.4

Rainbow Investments (Aust) Pty Ltd,

Brett Schwarz and Kermett Pty Ltd 9.5

Edward St Consulting Pty Ltd;

Iain Kirkwood 8.7

Roshi Blue Pty Ltd; Robert Kampf 7.2

Dr Ron Zmood; Zalpere Pty Ltd 5.6

Total - 393; Top 20 – 58.8M shares (67.7%)


20

Recent company announcements

May – Jun 2011 - Receive regulatory waiver from US FCC; close IPO; list on ASX

Nov 2011 - Execute Collaborative Evaluation & Pilot Agreements with ATCC and Corning

Jan – Mar 2012 - Secure $1.526M via private placement

May 2012 - Engage Plexus to manufacture commercial Matchbox™ reader; bluechiip® technology to be used at Australian Synchrotron

Jun - Jul 2012 - Secure first sales order from ATCC after completion of successful pilot trial; Appoint Ron Finkel to Board

Aug/Sep 2012 - Sign strategic partnership with Gentris Corporation; Engage Brett Roberts as Commercial Director

Oct 2012 – Granted patent in US



21

Anticipated near-term value inflexion points

• Launch of commercialization programs and secure sales

• Form partnerships with Route-to-Market partners i.e. distributors

• Enter co-development and license agreements

• Enter other market verticals

• Grant of patents

• Secure government grants

• Industry awards

• Other……



22

Opportunity & Next steps

• Opportunity

• To invest in Bluechiip Ltd as we enter the next growth phase

• Looking for new investors (retail, sophisticated, professional, institutional, strategic) to bolster the company’s share register

• Next steps

• Go to www.bluechiip.com – view announcements, articles, analyst reports, financials

• Speak to your broker re BCT

• Pick up 2012 Annual Report and brochure

• Contact Brett Schwarz

• Meet over 2 days of conference

• Mobile 0419 367 590

• Email [email protected]


http://www.bluechiip.com/



CONFIDENTIAL

The future of tracking is bluechiip®

“Is it bluechiiped?”

© bluechiip ® bluechiip and bluechiip (Logo) are registered trade marks of Bluechiip Ltd 23

Documents

Bluechiip Limited (ASX: BCT)present.knowledgevision.com/account/brr/assets/...Bluechiip Limited (BCT) should refer to all BCT ASX releases and statutory reports before considering